Liam Ratcliffe
CIK 1547100 · last filed 2026-08-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARVN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
40 WEST 57TH ST, 28TH FLOOR
NEW YORK, NY 10019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKUR | Director | — | $2.48 | — | $0 | 3 | 2026-08-11 |
| IRON | Director | — | $77.66 | — | $0 | 4 | 2026-06-23 |
| UPB | Director | — | $2.75 | — | $0 | 3 | 2026-06-11 |
| Climb Bio, Inc. (ELYM) Delisted | Director | — | $5.11 | — | $0 | 4 | 2024-06-28 |
| ARVN | Director | 421,935 | $7.31 | $3.08M | -$10.41M | 11 | 2022-06-21 |
| PASG | Director | 103,472 | $3.36 | $347.6K | $10.00M | 4 | 2021-05-28 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Director | 622,772 | — | — | $6.60M | 6 | 2019-06-18 |
| Aptinyx Inc. (APTX) Delisted | Director | 2,244,526 | $0.06 | $136.9K | $4.00M | 2 | 2019-04-02 |
| PDSB | Director | 1,182,434 | $1.06 | $1.26M | $0 | 1 | 2019-03-18 |
| EDGE | Director | — | $52.10 | — | $0 | 4 | 2018-08-15 |
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Director | 279,703 | $25.59 | $7.16M | $6.38M | 2 | 2018-05-21 |
| Aravive, Inc. (VSAR) Delisted | 10%+ Owner | 401,562 | — | — | -$22.81M | 1 | 2014-12-22 |
Recent Filings · Page 2 of 6
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-09 | IRON | Grant (A) | — | $0 | EDGAR |
| 2023-05-22 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-03 | — | Grant (A) | — | $0 | |
| 2022-06-21 | ARVN | Grant (A) | — | $0 | EDGAR |
| 2022-06-01 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-16 | ARVN | Sell (S) | −355,705 | -$23.83M | EDGAR |
| 2021-11-15 | ARVN | Sell (S) | −134,310 | -$11.53M | EDGAR |
| 2021-11-09 | ARVN | Mixed | −153,656 | -$15.46M | EDGAR |
| 2021-08-11 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-10 | ARVN | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.